Casdin Capital, LLC's Trading History
| WGSGeneDx Holdings | Jun 08, 2026 | Director, Ten Percent Owner | Informative Buy | 11.11M | $281.77M | |
| TSVT2seventy bio | Jun 12, 2024 | ― | Uninformative Buy | ― | $10.11M | |
| GBIOGeneration Bio | Jun 18, 2020 | ― | Uninformative Buy | ― | $8.60M | |
| FULCFulcrum Therapeutics | Jul 22, 2019 | Ten Percent Owner | Uninformative Buy | ― | $2.24M | |
| CNSTConstellation Pharmaceuticals | Jul 23, 2018 | ― | Uninformative Buy | ― | $5.40M |
You May Also Like
Casdin Capital, LLC insider profile FAQ
What is the percentage of profitable transactions made by Casdin Capital, LLC?
The percentage of profitable transactions made by Casdin Capital, LLC is 85%.
What is the average return per transaction made by Casdin Capital, LLC?
The average return per transaction made by Casdin Capital, LLC is 141.40%.
What stocks does Casdin Capital, LLC hold?
Casdin Capital, LLC holds: WGS, CNST, FULC, GBIO, TSVT stocks.
What was Casdin Capital, LLC’s latest transaction?
Casdin Capital, LLC’s latest transaction was an Informative Buy of $11.11M.
What was Casdin Capital, LLC's most profitable transaction?
Casdin Capital, LLC’s most profitable transaction was an Informative Buy of WGS stock on March 6, 2024. The return on the trade was 800.00%.
What is Casdin Capital, LLC's role in GeneDx Holdings?
Casdin Capital, LLC's role in GeneDx Holdings is Director, Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.